Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients with Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- ImCheck Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT05307874
- Locations
- 🇫🇷
IUCT Oncopole Claudius Regaud, Toulouse, France
🇩🇪University Carl Gustav Carus, Dresden, Germany
🇩🇪Universitätsklinikum Wuerzburg, Wuerzburg, Germany
First-in-Human Study of ICT01 in Patients with Advanced Cancer
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, AdultHematopoietic/Lymphoid Cancer
- Interventions
- Biological: IV ICT01
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- ImCheck Therapeutics
- Target Recruit Count
- 292
- Registration Number
- NCT04243499
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath